{"entity":{"id":"fid-007","kind":"drug","name":"FID-007","aka":["FID007","Paclitaxel in polyethyloxazoline polymer"],"tldr":"FID-007 is an experimental nanoencapsulated paclitaxel, a taxane chemotherapy from Fulgent Genetics, in phase 2 trials for head and neck squamous cell carcinoma, pancreatic cancer and ampullary cancer.","summary":"FID-007 (FID007, Paclitaxel in polyethyloxazoline polymer) is a nanoencapsulated paclitaxel, a taxane chemotherapy (polyethyloxazoline polymer) from Fulgent Genetics, with University of Southern California as partner. Paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer, designed to promote tumour penetration and retention. Its furthest stage is phase 2, for head and neck squamous cell carcinoma, pancreatic cancer and ampullary cancer. ClinicalTrials.gov registers it in 3 studies linked below. Randomised phase 2 with cetuximab in R/M HNSCC (NCT06332092) fully enrolled, active not recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Fulgent Genetics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm"},{"label":"Fulgent Genetics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm"},{"label":"Fulgent Genetics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT03537690"},{"label":"ClinicalTrials.gov: trials of FID-007","url":"https://clinicaltrials.gov/search?intr=FID-007"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["fulgent-genetics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06332092","nct03537690","nct06338657"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FID-007","modality":"Nanoencapsulated paclitaxel, a taxane chemotherapy (polyethyloxazoline polymer)","mechanism":"Paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer, designed to promote tumour penetration and retention.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fid-007/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"company":[{"id":"fulgent-genetics","kind":"company","name":"Fulgent Genetics","route":"/companies/fulgent-genetics/"}],"trial":[{"id":"nct06332092","kind":"trial","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06332092/"},{"id":"nct06338657","kind":"trial","name":"FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer","route":"/trials/nct06338657/"},{"id":"nct03537690","kind":"trial","name":"FID-007 in Treating Participants With Advanced Solid Tumors","route":"/trials/nct03537690/"}]}}